The administration of NAB815 at sub-bactericidal concentrations in patients with STEC infection could be an innovative treatment for the prevention of HUS, as Stx2a associated with EVs via TLR4 was detected in patients’ blood the day before HUS development.20 This evidence concerns the gene TLR4 and hemolytic-uremic syndrome.